Fostamatinib Production Cost Reports

The report provides a detailed analysis essential for establishing a Fostamatinib production plant. It encompasses all critical aspects necessary for Fostamatinib production, including the cost of Fostamatinib production, Fostamatinib plant cost, Fostamatinib production costs, and the overall Fostamatinib production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Fostamatinib production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Fostamatinib is an oral medication mainly used in the medical field for its immune-modulating properties. It is primarily prescribed for the treatment of immune thrombocytopenia (ITP) in adults, which leads to low platelet counts. It is mainly used as a medication in the treatment of chronic immune thrombocytopenia, which is a condition where the immune system destroys platelets and increases the risk of bleeding.

It works by inhibiting specific enzymes involved in immune signalling, which helps reduce platelet destruction and improve platelet counts. It is also being studied for potential use in treating autoimmune diseases like rheumatoid arthritis, autoimmune hemolytic anaemia, and IgA nephropathy. It is also being explored for use in other autoimmune and inflammatory conditions.

The primary factor that drives the market for Fostamatinib is its application as an oral drug in the treatment of immune-related blood disorders, which promotes its demand in the medical sector. Its application as a medication for the treatment of chronic immune thrombocytopenia (ITP) significantly contributes to its demand in the pharmaceutical industry.

Its demand as an oral drug in hospital or clinical care settings for the treatment of several inflammatory and immune-related conditions also fuels its demand in the medical and healthcare sectors. Its role as an important drug in managing disorders linked to abnormal immune system activity further drives its demand in the healthcare sector. Furthermore, industrial Fostamatinib procurement is influenced by factors such as raw material availability, cost considerations, regulatory approvals, and compliance with environmental standards. Advancements in production technologies, supplier reliability, sustainable production practices, and efficient supply chain management also play a crucial role in shaping the global procurement strategies for Fostamatinib.

Raw Material for Fostamatinib Production

According to the Fostamatinib production plant project report, the major raw materials for Fostamatinib production include Chloromethyl Sulfurochloridate, Potassium di-tert-butyl Phosphate, Aminopyridine, Triethylamine, and Sodium 2-ethylhexanoate.

Production Process of Fostamatinib

The extensive Fostamatinib production cost report consists of the following industrial production process:

1. Production via Chemical Synthesis: The production process of Fostamatinib begins with the preparation of a phosphate compound, di-tert-butyl (chloromethyl) phosphate, in a single step by reacting chloromethyl sulfurochloridate with potassium di-tert-butyl phosphate. Separately, pyrimidine is chlorinated using POCl3 at high temperature and then reacted with aminopyridine to form a pyrimidine compound. Further, this intermediate undergoes substitution with amine in aqueous NMP under heat to give an intermediate. Then, the phosphate side chain is introduced by alkylating the intermediate compound with phosphate. The resulting intermediate is extracted into i-PrOAc and treated with aqueous acetic acid, which removes the tert-butyl groups and causes precipitation of the phosphonic acid intermediate. This is converted into its DMF solvate and isolated after washing. In the final step, the DMF solvate is reacted with triethylamine in i-PrOH, followed by treatment with sodium 2-ethylhexanoate, which leads to the formation of Fostamatinib hexahydrate as the final product.

Fostamatinib is a spleen tyrosine kinase inhibitor used in the treatment of chronic immune thrombocytopenia in adults. It appears as a white to off-white powder and is formulated as the disodium hexahydrate salt in pharmaceutical preparations. The molecular formula of the base compound is C23H26FN6O9P, and its molecular mass is 580.47 g/mol. The compound is practically insoluble in a pH 1.2 aqueous buffer, slightly soluble in water, and soluble in methanol. The melting point of the compound ranges between 214 – 217 degree Celsius, and its boiling point is around 814.2 degree Celsius. It has a density of around 1.496 g/cm3. Common side effects include diarrhoea, hypertension, nausea, dizziness, increased liver enzymes, and neutropenia. The compound may cause serious adverse effects, including elevated blood pressure that requires regular monitoring, hepatotoxicity, severe diarrhoea, and increased risk of infections due to neutropenia. Additionally, the compound is contraindicated in pregnancy as it may cause fetal harm.